Correct Answer: B. Competitively blocking the binding of ACH to its receptors
Curare alkaloids (tubocurarine, atracurium, cisatracurium, vecuronium, rocuronium) are non-depolarizing neuromuscular blocking agents that work by competitive antagonism at the nicotinic acetylcholine receptors on the motor endplate. These agents structurally resemble acetylcholine but lack the ability to activate the receptor; instead, they bind reversibly to the α-subunits of the nicotinic ACh receptor, preventing acetylcholine from accessing its binding site. This competitive blockade is dose-dependent and can be overcome by increasing ACh concentration (hence why neostigmine, an anticholinesterase, is used to reverse their effects in Indian operating theatres). The blockade manifests as flaccid paralysis with preserved muscle tone initially, followed by characteristic fade on train-of-four stimulation. Curare agents do NOT cause depolarization—they prevent depolarization by blocking the excitatory signal. This mechanism distinguishes them from depolarizing agents like succinylcholine, which actually depolarize the membrane and cause fasciculations. In Indian anaesthetic practice, vecuronium and rocuronium are preferred for rapid sequence intubation due to their intermediate duration and predictable pharmacokinetics, while cisatracurium is favored in hepatorenal dysfunction due to Hofmann elimination.
Why the other options are wrong
A. Persistently depolarizing at neuromuscular junction — This describes succinylcholine (depolarizing agent), not curare. Curare causes flaccid paralysis without depolarization—it blocks the signal that would cause depolarization. Succinylcholine causes fasciculations and sustained depolarization; curare does not. This is a classic NBE trap pairing two opposite mechanisms. C. Inhibiting the calcium channels on presynaptic membrane — Presynaptic calcium channel inhibition would reduce ACh release, not block its receptor. Curare acts postsynaptically at the motor endplate receptor, not presynaptically. This option confuses the site of action—some agents (like magnesium) do affect presynaptic calcium, but curare's entire mechanism is receptor blockade at the endplate. D. Repetitive stimulation of ACh receptors on muscle endplate — This describes an agonist effect, not antagonism. Curare is a competitive antagonist—it blocks rather than stimulates receptors. Repetitive stimulation would cause depolarization and muscle contraction, the opposite of paralysis. This option reverses the fundamental mechanism.
High-Yield Facts
- Curare = competitive (non-depolarizing) antagonist at nicotinic ACh receptors; reversible blockade overcome by neostigmine.
- Succinylcholine = depolarizing agent; causes fasciculations and sustained depolarization—opposite of curare.
- Train-of-four fade is characteristic of non-depolarizing blockade; absent in depolarizing agents.
- Vecuronium and rocuronium are preferred intermediate-acting curare agents in Indian anaesthetic practice for RSI.
- Cisatracurium undergoes Hofmann elimination (temperature- and pH-dependent); safe in hepatorenal failure.
- Neostigmine reversal works only for non-depolarizing agents by increasing ACh concentration to overcome competitive blockade.
Mnemonics
CURARE = Competitive Antagonist (vs Succinylcholine) Curare = Competitive (blocks receptor, no depolarization, fade on TOF, reversed by neostigmine). Succinylcholine = Sustained depolarization (fasciculations, no fade, cannot reverse). Non-depolarizing agents: POST-synaptic blockade Curare blocks POST-synaptic ACh receptors (motor endplate). Remember: POST = Postsynaptic (curare), PRE = Presynaptic (magnesium, aminoglycosides).
NBE Trap
NBE pairs curare with depolarization (option A) to exploit confusion between the two major classes of neuromuscular blockers. Students who confuse succinylcholine's mechanism with curare's will select the wrong answer. The key discriminator is no fasciculations and no depolarization with curare.
Clinical Pearl
In Indian operating theatres, when a patient fails to recover from non-depolarizing blockade post-operatively, neostigmine 5 mg IV (with glycopyrrolate 1 mg to prevent muscarinic effects) is administered to reverse the competitive blockade by increasing ACh concentration—this reversal strategy only works because curare's blockade is competitive and reversible, not irreversible like depolarizing agents.
_Reference: KD Tripathi Pharmacology Ch. 11 (Neuromuscular Blocking Agents); Harrison Ch. 473 (Anesthesia)_